Clinical Trials Browser

Recruiting × Breast Neoplasms × Tamoxifen × Clear all

NCT05941520 2026-03-18

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-03-18

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04852887 2026-03-03

DEBRA

Phase 3 Recruiting

Breast Neoplasms

NCT06507618 2026-02-24

POWER II

Phase 3 Recruiting

Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Phase 2 Recruiting

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Phase 3 Recruiting

Breast Neoplasms

NCT05035836 2025-12-22

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Phase 2 Recruiting

Breast Neoplasms

NCT06364267 2025-11-18

BabyTears

Phase 2 Recruiting

Breast Neoplasms

NCT04569747 2025-11-13

ADEPT

Phase 2 Recruiting

Breast Neoplasms

NCT07190443 2025-09-29

AURA

Phase 3 Recruiting

Breast Neoplasms

NCT05512364 2025-08-19

TREAT ctDNA

Phase 3 Recruiting

Breast Neoplasms

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Phase 2 Recruiting

Breast Neoplasms

NCT05952557 2025-06-19

CAMBRIA-2

Phase 3 Recruiting

Breast Neoplasms

NCT05472792 2025-05-23

CAMERAN

Phase 2 Recruiting

Breast Neoplasms

NCT03011684 2025-05-08

TALES

Phase 3 Recruiting

Breast Neoplasms, Infertility

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

Breast Neoplasms

NCT05780567 2023-04-21

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Phase 3 Recruiting

Breast Neoplasms

NCT02062489 2022-04-27

Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients

Phase 3 Recruiting

Breast Neoplasms

NCT04666961 2022-04-22

HORNEO01

Phase 2 Recruiting

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating